Business
Penumbra, Inc. Reports First Quarter 2026 Financial Results
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.
About this update from Boston Scientific Corporation
[{"type":"text","content":"ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.","length":195,"tagName":"p"},{"type":"image","alt":"Penumbra, Inc. (PRNewsfoto/Penumbra, Inc.)","displaySize":"","headline":null,"caption":"Penumbra, Inc. (PRNewsfoto/Penumbra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":126,"url":"https://media.zenfs.com/en/prnewswire.com/eb15c61fcc22124ce31d956d65cd4d79"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBHrrlPeu3ktlRlchRPrRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyMg--/https://media.zenfs.com/en/prnewswire.com/eb15c61fcc22124ce31d956d65cd4d79","width":400,"height":126},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/M8kuTPk7ReWTDT3ULeY.OA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIwMg--/https://media.zenfs.com/en/prnewswire.com/eb15c61fcc22124ce31d956d65cd4d79","width":400,"height":126}},"href":"https://mma.prnewswire.com/media/2652215/Penumbra_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $374.8 million in the first quarter of 2026, an increase of 15.6% compared to the first quarter of 2025.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Global thrombectomy revenue of $253.9 million in the first quarter of 2026, an increase of 12.1% compared to the first quarter of 2025. ","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Global embolization and access revenue of $120.8 million in the first quarter of 2026, an increase of 23.8% compared to the first quarter of 2025. ","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit margin of 67.6% in the first quarter of 2026, an increase of 1.0% compared to the first quarter of 2025. ","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Total operating expenses of $215.2 million in the first quarter of 2026, comprised of R&D of $22.4 million and SG&A of $192.8 million, which includes $9.4 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.","length":299,"tagName":"p"}]},{"val":[{"type":"text","content":"Income from operations of $38.2 million a...